title: Has IL2 a role in the management of minimal residual disease for acute leukemia?
abstract: Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute leukemia patients. Here we shall discuss the biological and clinical observations which indicate that this innovative therapeutic approach may play a role in the management of minimal residual disease.
authors.affiliation: Dipartimento di Scienze Biomediche ed Oncologia Umana, Torino, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Foa
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: A
authors.initials: A
authors.lastname: Guarini
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: F
authors.initials: F
authors.lastname: Gavosto
mesh_terms: D000208:Acute Disease; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000627:therapeutic use*; D007938:Leukemia / Q000628:therapy*; D014162:Transfection
chemical_list: D007376:Interleukin-2